TREATMENT ADHERENCE TO CONVENTIONAL AND BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引:1
|
作者
Feldman, C. H. [1 ]
Lii, J. [1 ]
Gopalakrishnan, C. [1 ]
Franklin, J. M. [1 ]
Kim, S. C. [1 ]
机构
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
关键词
D O I
10.1136/annrheumdis-2018-eular.5544
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
THU0664
引用
收藏
页码:526 / 526
页数:1
相关论文
共 50 条
  • [21] AN UPDATED MIXED TREATMENT COMPARISON OF BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Rodriguez, M. F.
    Balmaceda, C.
    Espinoza, M. A.
    Rojas, R.
    Vargas, C.
    Dominguez, A.
    Duran, J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S95 - S96
  • [22] Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis
    Combe, Bernard
    JOINT BONE SPINE, 2006, 73 (06) : 587 - 590
  • [23] Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis
    Jin, Yinzhu
    Desai, Rishi J.
    Liu, Jun
    Choi, Nam-Kyong
    Kim, Seoyoung
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [24] Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis
    Desai, Rishi J.
    Hansen, Richard A.
    Rao, Jaya K.
    Wilkins, Tania M.
    Harden, Elizabeth A.
    Yuen, Andrea
    Jonas, Daniel E.
    Roubey, Robert
    Jonas, Beth
    Gartlehner, Gerald
    Lux, Linda
    Donahue, Katrina E.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (11) : 1491 - 1505
  • [25] The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States
    Ding, Qian
    Shiltz, Dane
    Hossami, Dana
    Konieczny, Alison M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (08) : 1231 - 1241
  • [26] POSTOPERATIVE COMPLICATIONS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGIC AND NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Pogozheva, E.
    Amirdzhanova, V.
    Makarov, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 374 - 375
  • [27] FACTORS ASOCIATED WITH THE INITIATION OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN TEXAS MEDICAID PATIENTS WITH RHEUMATOID ARTHRITIS
    Kim, G.
    Barner, J. C.
    Rascati, K. L.
    Richards, K. M.
    VALUE IN HEALTH, 2014, 17 (03) : A42 - A42
  • [28] Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Cho, Soo-Kyung
    Kim, Hyoungyoung
    Song, Yeo-Jin
    Kim, Hye Won
    Nam, Eunwoo
    Lee, Shin-Seok
    Lee, Hye-Soon
    Park, Sung-Hoon
    Lee, Yeon-Ah
    Park, Min-Chan
    Chang, Sung Hae
    Kim, Hyoun-Ah
    Kwok, Seung-Ki
    Kim, Hae-Rim
    Kim, Hyun-Sook
    Yoon, Bo Young
    Uhm, Wan-Sik
    Kim, Yong-Gil
    Kim, Jae Hoon
    Lee, Jisoo
    Choi, Jeongim
    Sung, Yoon-Kyoung
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (04): : 546 - +
  • [29] FACTORS ASSOCIATED WITH INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN MOROCCAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hammou, O.
    Chennouf, F.
    Azzouzi, H.
    Linda, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1441 - 1441
  • [30] Which Are The Most Common Disease Modifying Antirheumatic and Biologic Treatment Pathways For Rheumatoid Arthritis Patients?
    Pedro, Sofia
    Wolfe, Frederick
    O' Dell, James
    Michaud, Kaleb
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S721 - S721